Since the early 1970s, the synergistic activity of an aminoglycoside with a cell wall-active agent has been predicted by determining the ability of an enterococcus to grow in the presence of high levels of the aminoglycoside (usually >2,000 g/ml). However, a variety of media and concentrations of aminoglycosides has been used for this screening procedure. In the present study, we sought to optimize the agar dilution, broth microdilution, and disk diffusion tests used to detect high-level gentamicin and streptomycin resistance in enterococci. For dilution tests, brain heart infusion agar or broth gave the best growth and performance. For agar dilution, 500 g of gentamicin per ml, 2,000 g of streptomycin per ml, and an inoculum of 1 ؋ 10 6 CFU/ml were optimal, while for broth microdilution, 500 g of gentamicin per ml, 1,000 g of streptomycin per ml, and an inoculum of 5 ؋ 10 5 CFU/ml were best. Growth of more than one colony in the agar dilution test was determined to be the best indicator of high-level resistance. For disk diffusion, Mueller-Hinton agar, 120-g gentamicin disks, and 300-g streptomycin disks with breakpoints of no zone for resistance and >10 mm for susceptibility gave the best sensitivity and specificity if results for strains with zones of 7 to 9 mm are considered inconclusive, indicating that a broth or agar test should be performed to determine susceptibility or resistance.
CFU/ml were optimal, while for broth microdilution, 500 g of gentamicin per ml, 1,000 g of streptomycin per ml, and an inoculum of 5 ؋ 10 5 CFU/ml were best. Growth of more than one colony in the agar dilution test was determined to be the best indicator of high-level resistance. For disk diffusion, Mueller-Hinton agar, 120-g gentamicin disks, and 300-g streptomycin disks with breakpoints of no zone for resistance and >10 mm for susceptibility gave the best sensitivity and specificity if results for strains with zones of 7 to 9 mm are considered inconclusive, indicating that a broth or agar test should be performed to determine susceptibility or resistance.
As early as 1970 it was shown that the synergistic activity of an aminoglycoside with a cell wall-active antimicrobial agent (either a ␤-lactam agent or vancomycin) can be predicted by determining the ability of an enterococcus to grow in the presence of high levels of the aminoglycoside (usually Ն2,000 g/ ml). If high levels of aminoglycoside inhibit a strain and the strain is also susceptible to the cell wall-active agent, then synergy should be achieved (21, 36) . The first screening methods to detect high-level resistance (HLR) included an agar dilution test with dextrose phosphate agar (DPA) (21) and a broth macrodilution test with Trypticase soy yeast broth (36) , both with 2,000 g of streptomycin per ml. Since that time, however, many methods, inocula, and antimicrobial agent concentrations have been used to screen for HLR to aminoglycosides, and there appears to be no consensus as to the optimal screening method.
In recent years the incidence of nosocomial enterococcal infections has increased, making enterococci the second most common nosocomial pathogen reported to the National Nosocomial Infection Surveillance System (33) . In addition, the incidence of HLR to streptomycin and gentamicin in enterococci has increased (23) , making it important that clinical laboratories be able to reliably detect HLR to those two antimicrobial agents.
In 1991, the National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antimicrobial Susceptibility Testing formed a working group on enterococci to examine the problems associated with aminoglycoside testing. Given the lack of uniform detection methods, there was a need to determine reliable conditions and methods for the detection of HLR to aminoglycosides in enterococci. Consequently, the NCCLS working group on enterococci organized a multi-institutional study to evaluate three of the most commonly used methods (agar dilution, broth microdilution, and disk diffusion with high-content disks) by using strains whose mechanism(s) of resistance was characterized. This is a report of the results of that study.
MATERIALS AND METHODS
Study design. The study was conducted in four phases. Phase 1 involved the molecular characterization of the strains in one laboratory, and phase 2 involved the determination of the MICs of aminoglycosides for the strains by standard NCCLS methods (25) in two laboratories. Results of all tests performed during phases 1 and 2 were used to make a final determination of the susceptibility or resistance of the strains. In phase 3, a subset of organisms was chosen to evaluate the agar dilution, broth microdilution, and disk diffusion screening methods in seven laboratories in order to choose optimal conditions for the detection of HLR. In phase 4, the conditions chosen in phase 3 to give the best sensitivity and specificity were challenged in two laboratories by using seven lots of media obtained from four manufacturers and a series of genetically characterized isolates.
Participating laboratories. Phase 1 studies were conducted at the Centers for Disease Control and Prevention (CDC), Atlanta, Ga. Phase 2 studies were conducted at CDC and Massachusetts General Hospital (MGH), Boston, Mass. Phase 3 studies were conducted at seven laboratories: CDC; MGH; University of Chicago, Chicago, Ill.; Johns Hopkins Hospital, Baltimore, Md.; Duke Univer-sity, Durham, N.C.; University of Rochester, Rochester, N.Y.; and the University of California, Los Angeles. Phase 4 studies were performed at CDC and MGH.
Organisms. One hundred forty-six isolates (Table 1) were selected from the culture collections of the clinical microbiology laboratories at MGH, CDC, and the University of Chicago and from the collection of Carol Spiegel at the University of Wisconsin. The species distribution of the selected strains is provided in Table 1 . An effort was made to include a significant number of isolates for which streptomycin MICs were borderline (1,000 to 2,000 g/ml) and isolates for which problems had been demonstrated in prior tests or evaluations of methods. Organisms were kept frozen at Ϫ70ЊC in defibrinated sheep blood and were subcultured twice onto tryptic soy agar (TSA) with 5% sheep blood before use in any part of the study.
Fifty strains were selected for the multilaboratory study (phase 3). The strains were coded, refrozen, and shipped to the participating laboratories. Because two of those organisms were subsequently found to be contaminated, only 48 organisms were included in the data analysis of phase 3. For purposes of analysis of the data, the organisms were labeled as resistant or susceptible to gentamicin and streptomycin on the basis of the results of strain characterization obtained during phases 1 and 2 (see above), with emphasis given to susceptibility characterization by MIC determination and molecular characterization by PCR. A listing of the species and HLR patterns for the selected organisms is given in Table 1 . Twentysix of the strains were characterized as having HLR to streptomycin, including 15 strains for which MICs were borderline (MICs, 1,000 to 2,000 g/ml by broth microdilution); 27 strains had HLR to gentamicin, including 2 strains for which MICs were 1,000 to 2,000 g/ml. Fifteen strains were resistant to both gentamicin and streptomycin.
For phase 4, all 146 organisms were used, including 75 with HLR to streptomycin (30 for which MICs were borderline by the broth microdilution or agar dilution method) and 59 with HLR to gentamicin (2 for which MICs were borderline). Twenty-three organisms had HLR to both gentamicin and streptomycin.
Quality control. Four strains of Enterococcus faecalis were used for quality control during all phases of the study: ATCC 49532, a strain that has HLR to gentamicin but that is susceptible to streptomycin; ATCC 49533, a strain that is susceptible to gentamicin but that has HLR to streptomycin; and both ATCC 29212 and JH2-2 (15), strains that are susceptible to both gentamicin and streptomycin.
Antimicrobial agents. Streptomycin sulfate was obtained from Sigma (St. Louis, Mo.), and gentamicin sulfate was kindly provided by Schering Corporation (Kenilworth, N.J.).
Inoculum preparation. The inoculum for all susceptibility tests was prepared by making a suspension equal to a 0.5 McFarland standard from growth on an 18-to 24-h TSA sheep blood plate. For phase 3 testing, the same inoculum suspension was used to inoculate all three tests.
Phase 1: molecular characterization. The presence of the genes that encode the ANT(6)-I enzyme (for HLR to streptomycin) and the AAC(6Ј)ϩAPH(2Љ) enzyme (for HLR to gentamicin) (34) in the enterococcal isolates was confirmed by amplifying specific regions of those genes by PCR. The specificities of the products were confirmed by hybridization (7, 26) . The oligonucleotide primers chosen for amplification of the aac(6Ј), aph(2Љ), and ant(6)-I genes were selected from the published sequences (10, 11) with the assistance of OLIGO 3.4 software (National Biosciences, Hamel, Maine).
Briefly, four to five bacterial colonies from an overnight plate were suspended in the 100-l chilled reaction mixture containing 1ϫ PCR buffer (10 The primers chosen to detect the aac(6Ј)ϩaph(2Љ) gene were a forward primer (primer 348) 5Ј-TGA TGA TTT TCC TTT GAT GT-3Ј and a reverse primer (primer 1723) 5Ј-CAA TCT TTA TAA GTC CTT TT-3Ј (11) . The oligonucleotide primers chosen for amplification of the ant(6)-I gene were forward (primer 1268) 5Ј-ACT GGC TTA ATC AAT TTG GG-3Ј and reverse (primer 1845) 5Ј-GCC TTT CCG CCA CCT CAC CG-3Ј primers (10) .
Electrophoresis, staining, and electroblotting of the PCR products to nylon membranes were described previously (5). The DNA was fixed to the membrane by UV irradiation (GS Gene Linker; Bio-Rad Laboratories, Hercules, Calif.).
In those strains for which the results for HLR to gentamicin or streptomycin and molecular characterization did not agree, lysates were screened for the presence of aminoglycoside-modifying enzymes by the phosphocellulose binding assay described by Cooksey et al. (6) , except for modification of the wash buffer (10 mM Tris, 1 mM EDTA [pH 7.4]) and the suspension buffer (10 mM Tris, 10 mM MgCl 2 , 10 mM dithiothreitol [pH 6.8]) (3) .
Ribosomal resistance to streptomycin was determined by inoculating the strains onto plates containing DPA supplemented with 32,000 g of streptomycin per ml (9) and reading for any growth after 24 h of incubation at 35ЊC.
Synergy studies were performed in one laboratory (CDC) on organisms for which streptomycin or gentamicin MICs were considered borderline (500 or 2,000 g/ml), for those for which the results of the screening tests and the molecular characterization did not agree, for several strains for which no problem in the detection of susceptibility or HLR was demonstrated, and for several control strains. Synergistic activity results categorized by streptomycin MIC are given in Table 2 . The tests were done with dextrose phosphate broth (DPB) and either penicillin or vancomycin (for penicillin-resistant strains) plus streptomycin or gentamicin (21) . Viable counts were determined at 0, 4 to 6, and 24 h. Synergy was defined as a Ͼ100-fold increase in killing (Ͼ2 log 10 increments) at 24 h by the drug combination compared with the killing achieved by the most active of the drugs tested separately.
Phase 2: characterization of antimicrobial susceptibility. MICs were determined in Mueller-Hinton, brain heart infusion (BHI), and dextrose phosphate media by using plates prepared by NCCLS methods (25) for agar dilution and broth microdilution.
Phase 3: multilaboratory evaluation of screening methods. Agar dilution screen plates were prepared in one laboratory (CDC) by using Mueller-Hinton agar (MHA; MH II; Becton Dickinson Microbiology Systems, Cockeysville, Md.), BHI agar (BHIA; Difco, Detroit, Mich.), and DPB (Adams Scientific, West Warwick, R.I.) supplemented with 1 g of sodium citrate per liter and 15 g of Bacto Agar (Difco) per liter. The concentrations used were 500 and 2,000 g/ml for gentamicin and 500, 1,000, and 2,000 g/ml for streptomycin. The final inoculum was 10 6 CFU per spot, which was achieved by spotting the surface of the agar with 10 l of the 0.5 McFarland suspension. Results were read as positive if confluent growth was present, as weak if a light, confluent haze was visible, as the number of colonies if they were countable (usually Ͻ30), and as negative if there was no growth. Readings were done at 18, 24, and 48 h. For purposes of the final designation of positive or negative, weak growth was considered positive, as was the presence of more than one colony.
Broth microdilution plates were prepared by two commercial manufacturers (MicroScan, West Sacramento, Calif., and Pasco Laboratories, Wheat Ridge, Colo.) by NCCLS methods (25) . Both manufacturers prepared frozen panels with the same antimicrobial agent stock solutions and the same lots of broth. The broths used included cation-adjusted Mueller-Hinton broth (CAMHB; Becton Dickinson Microbiology Systems), Difco Mueller-Hinton broth (MHB) adjusted on preparation to contain cations, as currently recommended by NCCLS (CAMHB) (25) and recommended previously (CSMHB) (24) a The highest single MIC result from phase 2 of the study was used. b When multiple synergy tests were run with same strain, the result is expressed as the most synergistic, i.e., if there was both a 1.5-log 10 increase in killing and no increase in killing at different times, the 1.5-log 10 increase was used.
c Strain 211 (see Table 3 ). Baltimore, Md.), Adams MHB (Adams Scientific) containing calcium chloride and magnesium sulfate, BHI broth (BHIB; Becton Dickinson Microbiology Systems), Difco BHIB, and Adams Scientific DPB with (DPBC) and without (DPB) 1 g of sodium citrate per liter. The concentrations in the panels included 2,000, 1,000, and 500 g of both antimicrobial agents per ml. The inoculum for the broth microdilution tests was adjusted so that the final number of organisms in the microdilution wells was 5 ϫ 10 4 CFU (5 ϫ 10 5 CFU/ml). Plates were read after 18, 24, and 48 h of incubation. Wells were read as positive if growth was easy to read, weak if growth was faint or hard to read, and negative if there was no growth. For purposes of analysis of the data, weak growth was considered positive.
Disk diffusion zone diameters were determined on commercially prepared MHA and MHA with 5% sheep blood (kindly provided by Becton Dickinson Microbiology Systems). The same lots of both media were tested in all seven laboratories. Gentamicin disks (120 g) and streptomycin disks (300 g) were provided by Becton Dickinson Microbiology Systems, Difco, and Remel (Lenexa, Kans.).
Phase 4: evaluation of BHIB, BHIA, and MHA from different manufacturers. The streptomycin stock solution was prepared in one laboratory, frozen, and then distributed for use in the preparation of both the broth microdilution and agar dilution plates used in phase 4. Agar dilution screen plates were prepared and tested in one laboratory (MGH) by using streptomycin at 2,000 g/ml and BHIA powder obtained from Becton Dickinson Microbiology Systems, Difco, Adams Scientific, Acumedia, and Oxoid. Both BHIA and modified BHIA from Becton Dickinson Microbiology Systems were used (modified BHIA contains a different amount of BHI and peptic digest of animal tissue and casein than the manufacturer's regular BHIA). In addition, the same lot of BHIA used in phase 3 (Difco) was included in phase 4 (designated the common lot). Inoculum preparation and reading were done as described for phase 3, except that reading was done at 24 and 48 h only.
Broth microdilution plates were prepared and tested in one laboratory (CDC) by using BHIB obtained from Becton Dickinson Microbiology Systems, Difco, Adams Scientific, Acumedia, and Oxoid. Both BHIB and modified BHIB were from Becton Dickinson Microbiology Systems. In addition, the same lots of BHIB from both Becton Dickinson Microbiology Systems and Difco that were used in phase 3 were included in this phase (designated common lots). Plates were prepared with streptomycin at 2,000, 1,000, and 500 g/ml and gentamicin at 500 g/ml. Plates were inoculated and read as described for phase 3, except that reading was done at 24 and 48 h only.
For disk diffusion testing, MHA plates were kindly provided by Becton Dickinson Microbiology Systems (MH II) and Remel (using Difco MHA). In addition, plates were prepared at CDC by using Oxoid MHA. The same disks used in phase 3 were tested in phase 4. Testing was done in one laboratory only (CDC).
Data analysis. Determination of a strain's HLR was made after data from phases 1 and 2 were analyzed. Sensitivity was defined as the percentage of strains with HLR that were correctly categorized; specificity was defined as the percentage of susceptible strains that were correctly categorized. For phase 3 (see Tables  4 to 8) , data from all seven laboratories were combined so that there were 336 results for each drug and concentration tested (48 strains tested in seven laboratories).
RESULTS

Strain characterization.
Results of MIC testing with Mueller-Hinton media were used to establish the susceptibility phenotypes of the strains. In general, MICs determined by both laboratories (CDC and MGH) with BHI medium were higher than those determined with Mueller-Hinton medium (data not shown). This was especially true with MICs determined by broth microdilution testing (data not shown).
Confirmation of HLR to gentamicin by molecular studies was excellent. For streptomycin, nine strains displayed discrepancies between their susceptibility phenotype, molecular characterization for the ant(6)-I gene by PCR, and synergy tests. The characteristics of these strains are given in Table 3 . For one strain (strain 211) the streptomycin MIC was never above 250 g/ml when the strain was tested with Mueller-Hinton medium, but the strain was positive for the gene for the ANT(6)-I enzyme by PCR and was not killed in synergy studies. It was considered resistant for data analysis purposes. For three strains (strains 476, 538, and M108) for which streptomycin MICs on Mueller-Hinton medium were consistently Ն2,000 g/ml, we failed to detect a known mechanism of resistance by any genetic method or by testing ribosomal resistance. No synergism against these isolates was detected by time-kill studies, although for one isolate (strain 476) a 1-to 2-log 10 increase in killing was observed. These organisms were considered streptomycin resistant for data analysis. In addition, for one strain (strain 758) streptomycin MICs were Յ500 g/ml and synergistic activity against the organism was detected in time-kill studies, but the organism tested positive for the gene encoding the ANT(6)-I enzyme but was negative in aminoglycoside-modifying enzyme assays. The strain was categorized as streptomycin susceptible for data analysis.
Four organisms (strains 208, 378, 566, and 735) were responsible for the majority of the specificity problems with streptomycin. The streptomycin MICs for these strains were higher than normal when Mueller-Hinton medium was used; with BHI medium, the MICs were Յ1,000 g/ml. None of the strains was positive for the gene encoding the ANT(6)-I aminoglycoside-modifying enzyme by PCR or by enzyme assays, but for two strains equivocal synergistic activity was demon- strated in time-kill studies. Because of the equivocal drug synergy results, the susceptible phenotype, and the lack of molecular confirmation of resistance, these strains were classified as streptomycin susceptible. Phase 3. Agar dilution screen results are given in Table 4 . For gentamicin, sensitivity and specificity were excellent at all three time periods when the drug was used at 500 g/ml. For streptomycin, the medium and concentration had a more pronounced effect on the results. The test with 500 g of streptomycin per ml was very sensitive, but it lacked specificity. The specificity with 1,000 g of streptomycin per ml improved at 24 h on all media, but the best results were obtained with 2,000 g/ml. Sensitivity and specificity of Ն95% were achieved only when the readings taken at 48 h were used, resulting in essentially equivalent sensitivities and specificities for all four media tested, although growth was either easier to read or more clear-cut on BHIA and DPA. In addition, readings at 24 h designated weak were more often noted with MHA (31% of the readings versus 10 to 13% of the readings for BHIA and DPA, respectively).
For the agar dilution test no growth or the growth of one colony was considered to indicate susceptibility; the growth of more than one colony indicated HLR. The occurrence of one colony was noted during phase 3 almost exclusively with tests with streptomycin. For the strains positive for HLR to streptomycin, 7 of 189 (3.7%) test results with BHIA at 24 h were recorded as one colony. All but two tests resolved at 48 h, and the strains would have been correctly noted as positive for HLR. For the strains negative for HLR to streptomycin, 7 of 154 (4.5%) test results recorded at 24 h were noted as one colony; only one test changed to more than one colony at 48 h.
The data generated with BHI by the broth microdilution test during phase 3 are given in Tables 5 and 6 . For phase 3 testing of gentamicin with BHIBs (Table 5) , the sensitivity and spec- ificity were Ն95% for all concentrations at all three time periods, but the best results were obtained with gentamicin at 500 g/ml. Consequently, that concentration was chosen for further study in phase 4. Results were less clear-cut for streptomycin (Table 6 ). The best combination of sensitivity and specificity was obtained with streptomycin at 1,000 g/ml: sensitivity ranged from 92 to 99% at 24 h and slightly improved to 96 to 99% at 48 h. Specificity was slightly better at 24 h (96 to 99%) than at 48 h (93 to 99%). Data for tests with MHB and DPB are not shown. Results obtained with two of the MHBs (Becton Dickinson Microbiology Systems CAMHB and Adams MHB with calcium and magnesium) were not evaluated, because both media caused a faint precipitate in some of the wells that interfered with read- For streptomycin, the effects of the media were most obvious at 1,000 and 2,000 g/ml; sensitivity with MHB was much lower than that with the two richer media, BHIB and DPB. With streptomycin at 500 g/ml, there was better agreement among the three media, but for two of the MHBs used, the sensitivity was less then 95% at 24 h. Results with DPB were comparable to those with BHIB (data not shown). The broth microdilution plates prepared for us by Pasco and MicroScan produced results that were essentially equivalent for both gentamicin at 500 g/ml and streptomycin at 1,000 g/ml with the BHIBs.
The disk diffusion results from phase 3 testing are presented in Table 7 (for unsupplemented MHA) and Table 8 (for MHA supplemented with 5% sheep blood) as the percentage of strains with zones of 6 mm (no zone), 7 to 9 mm, and Ն10 mm. For disk diffusion, sensitivity is defined as the percentage of resistant strains with zones of Ͻ10 mm; specificity is defined as the percentage of susceptible strains with zones of Ն10 mm. With unsupplemented MHA (Table 7) with gentamicin, sensitivity was excellent (99 to 100%) at both 18 and 24 h; specificity, however, decreased slightly at 24 h (94 to 96%) compared with that at 18 h (96 to 98%). For streptomycin, sensitivity was 96 to 97% at both 18 and 24 h, but specificity was poor at both times (82 to 93% at 18 h and 81 to 89% at 24 h). However, if results for strains with zones of 7 to 9 mm are classified as inconclusive, which would warrant another test, then specificity for streptomycin would increase to 96 to 98% at both 18 and 24 h. With MHA supplemented with sheep blood (Table 8) , sensitivity was good for gentamicin (97 to 99% at 24 h) but poor for streptomycin (88 to 96% at 24 h).
Medium. During the phase 3 study growth was clearly much better and easier to read when the two richer media, BHI and dextrose phosphate media, were used. Weak results were reported more often with Mueller-Hinton medium than with BHI medium or dextrose phosphate medium. Because dextrose phosphate medium is not prepared by all medium manufacturers and because many investigators already use BHI medium for screening methods, BHI medium was chosen as the most widely available medium for screening for HLR. Because some manufacturers were concerned about the lot-tolot variation with BHI medium, it was decided at the end of phase 3 to look at the performance of all manufacturers' BHI media in phase 4. Phase 4. Because gentamicin performed well when it was tested by the agar dilution screen during phase 3, it was not tested further by this method in phase 4. For multiple lots of BHIA with streptomycin at 2,000 g/ml (Table 9) , sensitivity was Ͻ90% (when the 146 organisms were tested in one laboratory) for both of the lots of BHIA from Becton Dickinson Microbiology Systems and the lot from Oxoid tested at 24 h. However, Ն95% sensitivity was again achieved at 48 h for all media examined. For broth microdilution with gentamicin at 500 g/ml (data not shown), sensitivity was 100% and specificity was 99 to 100% for all BHIBs examined at both 24 and 48 h. For broth microdilution with streptomycin at 1,000 g/ml (Table 10) , sensitivity was Ն95% and specificity was 99 to 100% for all BHIBs.
For disk diffusion testing with MHA media from three manufacturers and 146 strains (phase 4), sensitivity and specificity for gentamicin were Ն98% at both 24 and 48 h (data not shown). With streptomycin (Table 11) , sensitivity was 93 to 99% at 18 h. However, it improved to Ն97% at 24 h for the three media used.
DISCUSSION
Enterococci are inherently resistant to aminoglycosides, which makes this class of drugs unsuitable for use as single agents in the treatment of enterococcal infections (23) . The normal MICs of penicillin and ampicillin for enterococci are also elevated compared with the MICs for streptococci, varying from 1 to 8 g/ml for E. faecalis and 4 to 32 g/ml or greater for Enterococcus faecium (8, 23) . In addition, neither penicillin, ampicillin, nor aminoglycosides are bactericidal against enterococci (8). However, despite intrinsic low-level resistance, serious enterococcal infections can be treated with penicillin, ampicillin, or vancomycin plus an aminoglycoside in the absence of HLR (8) because the two agents act synergistically. However, if the enterococcus is resistant to the ␤-lactam agent or vancomycin or to high levels of the aminoglycoside, the utility of these agents in combination therapy is essentially lost.
Determination of the ability of an enterococcus to grow in the presence of high concentrations of aminoglycosides has been used since the early 1970s to predict synergistic activity with a cell wall-active agent (22, 36) . Moellering et al. (22) , and 10 6 CFU per spot) using 63 E. faecalis strains (35 with HLR to streptomycin and 22 with HLR to gentamicin). Using results of time-kill synergy tests to characterize resistance with gentamicin at 2,000 g/ml and an inoculum of 10 6 CFU per spot, they found 95% sensitivity with all four media; for streptomycin, sensitivity was 100% with BHIA, DPA, and TSA, but sensitivity was slightly lower with MHA (97%). Specificity was 100% for gentamicin and 96 to 100% for streptomycin with all four media. Weissmann et al. (39) found that the use of Mueller-Hinton medium in a broth microdilution screen with streptomycin at a concentration of 2,000 g/ml contributed to failures to detect enterococci with HLR to streptomycin mediated by enzyme production and recommended the use of DPB. Other investigators have used an agar dilution screen test as the reference method and therefore have not evaluated it against other methods (4, 12-14, 19, 29, 30, 37, 39-41) . In those studies, the most common medium used was BHIA, and the concentrations tested ranged from 500 to 2,000 g/ml for gentamicin and from 1,000 to 2,000 g/ml for streptomycin.
For agar dilution testing during phase 3 in our study, we found that all four media performed essentially alike, although growth was easier to detect on BHIA and DPA. With 500 g of streptomycin per ml, specificity with BHIA was slightly lower than that with the other media tested. However, perfor- Adams  99  99  0  1  Acumedia  95  99  0  0  BDMS  99  97  0  0  BDMS modified  96  99  0  0  BBL common  96  96  0  0  Difco  99  99  0  1  Difco common  99  99  0  0  Oxoid  99  99  0  0 a BDMS modified, modified BHI medium from Becton Dickinson Microbiology Systems; common lots were those used in phase 3 testing (Tables 3 and 4) . mance varied with different concentrations. For gentamicin, performance with both concentrations (500 and 2,000 g/ml) was good, but sensitivity with 500 g/ml was slightly better than that with 2,000 g/ml. For streptomycin, a concentration of 500 g/ml was sensitive but not specific. With 1,000 g of streptomycin per ml, sensitivity remained the same and specificity improved, but specificity was still Յ95% at 24 h. To achieve Ͼ95% sensitivity and specificity, it was necessary to use 2,000 g of streptomycin per ml for agar dilution screen testing and to incubate the plates for a full 48 h. For evaluating this phase of testing, the results from each of the seven laboratories for the 48 strains studied were combined. Most errors occurred in only one or two laboratories, and most were resolved at 48 h, at which time the sensitivities and specificities of the tests at all of the laboratories ranged from 89 to 100% (tests at six of seven laboratories achieved sensitivities of Ͼ96%; tests at all seven laboratories had specificities of Ͼ96%). The only consistent error in sensitivity was with strain 211, for which streptomycin MICs were low on repeat testing, but the strain was categorized as resistant by both the presence of the gene encoding the streptomycin-modifying enzyme ANT(6)-I (as determined by PCR analysis) and the lack of synergistic activity against the strain in time-kill studies.
In phase 4 agar dilution testing (Table 9 ), errors occurred with 11 of the 75 strains with HLR to streptomycin; for all of these strains, streptomycin MICs were borderline. Acumedia and Difco BHIAs performed the best of the five brands tested during that phase.
In studies that have compared broth microdilution screen methods with other methods, all have used MHB (4, 29, 30, 35, 41) and all have found few problems in detecting gentamicin resistance with a gentamicin concentration of 500 g/ml. In two studies (29, 35) , a gentamicin concentration of 500 g/ml was more sensitive than a concentration of 2,000 g/ml. In contrast, most studies have reported some difficulty in detecting streptomycin resistance with streptomycin at a concentration of 2,000 g/ml; sensitivities were 79% (29), 86% (30), 89% (35) , 92% (4), and 100% (41) . In two separate studies, it was found that increasing the incubation time to 48 h improved the detection of streptomycin resistance by the broth microdilution method (29, 39) .
For gentamicin, sensitivity and specificity of the broth microdilution test were excellent at all concentrations, but they were best when 500 g/ml was used and reading was done at 24 h (Table 5 ). For streptomycin (Table 6 ), the most effective parameters were not as obvious. Sensitivity was very good with streptomycin at 500 g/ml, but specificity was poor, especially when Difco BHIB was used, whereas the reverse was true for testing with streptomycin at 2,000 g/ml. The best combination of sensitivity and specificity was achieved with 1,000 g/ml, although with the medium from Becton Dickinson Microbiology Systems, the sensitivity was not quite as good as that with the medium from Difco. Since the results from all seven laboratories were combined for this phase, each of the 48 strains included in the study was used seven times for evaluation. The most significant errors, then, would be with the resistant organisms that were missed in more than one or two laboratories. More than half of the resistant organisms included in phase 3 were characterized as being borderline resistant to streptomycin, and as such, they would be the most difficult to detect. Only two strains were missed in more than two laboratories: one strain characterized as being borderline resistant and strain 211, for which the MICs were consistently less than 1,000 g/ml (see above). The specificity errors occurred among seven isolates, with only one error (involving a strain [strain 566] for which MICs indicated borderline susceptibility) occurring in more than two laboratories. In phase 4 broth microdilution testing (Table 10) , streptomycin sensitivity errors occurred among six strains; five for which MICs indicated borderline resistance and strain 211 (described above), which was missed in all of the broths evaluated at both 24 and 48 h. Sensitivity was 95 to 99% at 24 h and improved slightly at 48 h.
The broth microdilution plates used in our study during phase 3 were prepared for us by both MicroScan and Pasco, but both manufacturers used the same drug stocks and broths when manufacturing the plates and prepared the plates according to the recommendations of NCCLS (25) . In addition, when testing was performed, the final inoculum used was 5 ϫ 10 5 CFU/ml, as recommended by NCCLS (25) . By using the final parameters chosen, both plates performed well and the results obtained with both plates were comparable to each other. We did find that one of the BHIBs examined (that from Becton Dickinson Microbiology Systems) was slightly less sensitive at 24 h (Table 10 ), but sensitivity improved at 48 h. The other BHIB (that from Difco) was more sensitive at 24 h, but it was less specific when incubation was extended to 48 h.
In 1982, Rosenthal and Freundlich (28) reported the successful use of disks containing higher than normal concentrations of aminoglycosides. With 120-g gentamicin and 300-g streptomycin disks, strains for which MICs were Ն4,000 g/ml had no zones of inhibition when they were tested on MHA or TSA supplemented with 5% sheep blood. However, they tested only small numbers of strains with HLR to these antimicrobial agents. In 1984, Pfaller et al. (27) confirmed that disks containing the usual 10-g amounts of gentamicin and streptomycin could not distinguish susceptible strains from those with HLR. Jenkins et al. (16) showed that when MHA is supplemented with sheep blood, zones of inhibition with 10-g aminoglycoside disks are about 6 mm larger than those when unsupplemented medium is used.
In 1988, Sahm and Torres (32) confirmed that the strains with HLR to gentamicin or streptomycin (20 of each type) that they tested had zones of Ͻ10 mm on both supplemented and unsupplemented MHA but that the use of sheep blood-supplemented agar resulted in larger zones of inhibition for susceptible strains. In a later study, Sahm et al. (29) showed good agreement between a disk diffusion procedure with high-content disks and an agar screen procedure, but they did find several strains with zones of inhibition right at the breakpoint of 10 mm. They characterized these strains as susceptible. Later studies have shown excellent correlation of the results of the high-content disk diffusion procedure and the presence or absence of HLR (20, 30, 35, 38 ) when a breakpoint of Ͻ10 mm was used for the detection of resistance. Other investigators have used different breakpoints (2) or disks containing different amounts of aminoglycoside (17, 18) .
In our study, we found excellent performance of the highcontent disk diffusion screen for the detection of HLR to gentamicin, with sensitivity of 99 to 100% in both phases 3 and 4. Specificity was also very good, but the test did categorize 2 to 5% of susceptible strains as gentamicin resistant (zones, Ͻ10 mm), with zones in the range of 7 to 9 mm (data not shown). Except in one instance, those strains would have been correctly categorized by either the agar dilution or the broth microdilution screening test.
Again, the results for streptomycin were not as good. The disk diffusion screen failed to detect 3 to 4% of the isolates with HLR to streptomycin. However, in almost all instances zones of Ͼ10 mm for isolates designated HLR occurred with the one problem strain included in the study (strain 211; see description above). This strain was also miscategorized by both the agar dilution and the broth microdilution screen tests.
The specificity errors with the high-content streptomycin disk occurred almost exclusively with four susceptible organisms for which streptomycin MICs are higher than normal (strains 208, 378, 566, and 735). For these four strains streptomycin MICs are 250 to 500 g/ml when tested with MuellerHinton medium; with BHI medium the MICs are usually 500 to 1,000 g/ml. We did not detect the presence of the gene for the streptomycin-modifying enzyme ANT(6)-I in these strains. In time-kill studies, synergistic activity against the strains was variable, with activity against two of the strains being equivocal and that against two other strains being nonexistent. By the other screening methods, these four strains were most often categorized as susceptible. For two additional strains streptomycin MICs were 500 g/ml with Mueller-Hinton medium, and synergistic activity was demonstrated against the strains (data not depicted in Table 3 ).
As has been seen by others (16, 32) , MHA supplemented with sheep blood resulted in larger zones of inhibition than those obtained in unsupplemented agar, a condition which resulted in more false susceptibility, especially for streptomycin. A higher breakpoint could not be used because overlap among the susceptible and resistant strains would have resulted in the opposite condition, i.e., a high percentage of false-positive results for resistance to streptomycin. Therefore, for determining HLR to aminoglycosides, the use of MHA with sheep blood is discouraged.
Other investigators have recently proposed the use of different high-content disks (500 g of streptomycin and 250 g of gentamicin) and have used lower breakpoints for categorizing HLR (streptomycin, Ն256 g/ml; gentamicin, Ն128 g/ml) (1, 17, 18, 26) . However, in those studies the breakpoints were used to categorize the MICs that were generated with MHA and a standard agar dilution inoculum of 10 4 CFU per spot. When characterizing 550 enterococcal strains resistant by using those breakpoints, Ounissi et al. (26) found 65 strains (12%) that did not hybridize with the ant(6)-I probe (26) . Of those 65 (4) . c If the zone is 7 to 9 mm, the test is inconclusive and an agar dilution or broth microdilution test should be performed to confirm susceptibility or resistance. strains only 10 were examined for the presence of ribosomal resistance (9) and of those only 3 were found to be resistant by that mechanism, leaving the majority of discrepancies unexplained. Bantar et al. (1) recently reported the results of synergy testing of 14 E. faecalis strains that were categorized by using the more conservative breakpoints of Ounissi et al. (26) , calling strains for which gentamicin MICs were 512 g/ml and streptomycin MICs were 256 to 1,024 g/ml moderately highlevel resistant. They found that synergistic activity against all 14 strains was lacking when they were tested by time-kill studies. Of the six strains in our study for which streptomycin agar dilution MICs were 500 g/ml, activity against two of the strains (strains 208 and 278) was not synergistic by the time-kill method, synergistic activity against two of the strains (strains 566 and 735) was equivocal, and activity against two strains was synergistic (data not shown). In our study all but one strain (strain 211) for which streptomycin MICs were Ͻ1,000 g/ml by the agar dilution method with MHA did not produce the ANT(6)-I enzyme. Thus, we believe that the higher breakpoints are more appropriate on the basis of the mechanisms of resistance known to be common in this population.
Strains that were positive for the ant(6)-I gene (except strain 211) and for which streptomycin MICs (250 to 1,000 g/ml) indicated borderline resistance were usually characterized as resistant in our study by all of the screening methods. These strains, however, did account for the majority of the sensitivity errors at 24 h. Most errors were resolved at 48 h, and the strains were correctly categorized as resistant. Similarly, ant(6)-I gene-negative, streptomycin-susceptible strains for which MICs (250 to 500 g/ml) were higher than normal were usually characterized as susceptible except by the disk diffusion method. Since we believe that the use of streptomycin is likely reserved for occasions when HLR to gentamicin exists, it may be preferable to be less conservative when categorizing these strains for susceptibility to streptomycin. In addition, since clinical evidence that would support lowering the breakpoint for HLR is lacking and since the strains for which MICs indicate borderline resistance do not appear to be clearly categorized by time-kill studies, we have chosen to continue to use the parameters for the agar dilution test that were originally described by Moellering et al. (22) , except that the inoculum is now standardized to 10 6 CFU per spot. In summary, the screening methods used to detect high-level gentamicin and streptomycin resistance in enterococci are listed in Table 12 .
